Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUDC-101 pharmacodynamic and pharmacokinetic window study in HER2-positive invasive breast cancer
2012-003064-47Phase 2Terminated
- Sponsor
- Curis, Inc.
- Start
- Jul 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cudc-101 in breast cancer, sponsored by Curis, Inc. Primary endpoint: Change in Ki-67 and AcH3 in paired tumor biopsies. Started Jul 2012; status: terminated.
02
Drugs
cudc-101
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2012-003064-47.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003064-47.